Clopidogrel Bolus is Inferior to Sustained Clopidogrel Pretreatment in Patients Undergoing Carotid Artery Stent Placement

BACKGROUND: Clopidogrel bolus is an option used before carotid artery stent (CAS) placement when sustained clopidogrel pretreatment is not used. OBJECTIVE: To compare the effect of clopidogrel bolus (450 mg administered ≥4 hours) with sustained clopidogrel pretreatment (48 hours or greater) before CAS among patients recruited in the Carotid Revascularization Endarterectomy versus Stenting Trial. METHODS: We compared the rates of primary end point (either any stroke, myocardial infarction, or death during the periprocedural period or any ipsilateral stroke within 4 years) between patients who received clopidogrel bolus and those who received sustained clopidogrel pretreatment using Cox proportional hazards analysis after adjusting for age, sex, symptomatic status, and initial severity of stenosis (≥70% vs <70%) over 4 years. RESULTS: The rate of periprocedural stroke (7.3% vs 3.4%, P = .03) and primary end point (11.3% vs 5.9%, P = .02) was significantly higher among patients who received clopidogrel bolus. The risk of primary end point was significantly higher in patients who received clopidogrel bolus (hazards ratio 1.9, 95% CI 1.1–3.4, P = .02) after adjusting for potential confounders. The overall mean (±standard deviation) primary end point–free survival based on Kaplan–Meier analysis was 7.0 ± 0.2 years for patients who received clopidogrel bolus and 8.9 ± 0.1 years for those who received sustained clopidogrel pretreatment (log-rank test P = .011). CONCLUSION: Clopidogrel bolus was associated with higher rates of adverse outcomes compared with sustained clopidogrel pretreatment in patients who underwent CAS. Therefore, clopidogrel bolus may not be equivalent to sustained clopidogrel pretreatment.

[1]  K. Houlind,et al.  Low Risk of Neurological Recurrence while Awaiting Carotid Endarterectomy: Results From a Danish Multicentre Study. , 2021, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[2]  A. Qureshi,et al.  The Effect of Ticagrelor on Platelet Reactivity in Patients with Clopidogrel Resistance Undergoing Neuroendovascular Procedures , 2020, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[3]  Chaofen Chen,et al.  Impact of periprocedural myocardial injury on long-term clinical outcomes of chronic total occlusion patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis , 2019, Coronary artery disease.

[4]  P. Serruys,et al.  TCT-308 Impact of Periprocedural Major Adverse Events After PCI and CABG on Long-Term Outcomes in Patients With Left Main Disease: The EXCEL Trial , 2019, Journal of the American College of Cardiology.

[5]  B. Baxter,et al.  WEAVE Trial: Final Results in 152 On-Label Patients , 2019, Stroke.

[6]  B. Brott,et al.  Ticagrelor and Eptifibatide Bolus Versus Ticagrelor and Eptifibatide Bolus With 2‐Hour Infusion in High‐Risk Acute Coronary Syndromes Patients Undergoing Early Percutaneous Coronary Intervention , 2017, Journal of the American Heart Association.

[7]  V. Howard,et al.  Long-Term Results of Stenting versus Endarterectomy for Carotid-Artery Stenosis. , 2016, The New England journal of medicine.

[8]  W. Gray,et al.  Randomized Trial of Stent versus Surgery for Asymptomatic Carotid Stenosis. , 2016, The New England journal of medicine.

[9]  K. Ellemann,et al.  Risk of early recurrent stroke in symptomatic carotid stenosis after best medical therapy and before endarterectomy , 2016, International journal of stroke : official journal of the International Stroke Society.

[10]  V. Cairns,et al.  Dual Antiplatelet Therapy Prior to Expedited Carotid Surgery Reduces Recurrent Events Prior to Surgery without Significantly Increasing Peri-operative Bleeding Complications. , 2015, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[11]  J. Sédat,et al.  Administration of eptifibatide during endovascular treatment of ruptured cerebral aneurysms reduces the rate of thromboembolic events , 2015, Neuroradiology.

[12]  A. Qureshi,et al.  Factors Associated with Increased Rates of Post-procedural Stroke or Death following Carotid Artery Stent Placement: A Systematic Review. , 2014, Journal of vascular and interventional neurology.

[13]  H. Kim,et al.  Thromboembolic Complications in Patients with Clopidogrel Resistance after Coil Embolization for Unruptured Intracranial Aneurysms , 2014, American Journal of Neuroradiology.

[14]  W. Freeman,et al.  Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience , 2013, Journal of NeuroInterventional Surgery.

[15]  Seung‐Jung Park,et al.  Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. , 2013, European heart journal.

[16]  A. Berenstein,et al.  Clopidogrel Resistance Is Associated with Thromboembolic Complications in Patients Undergoing Neurovascular Stenting , 2013, American Journal of Neuroradiology.

[17]  L. Churilov,et al.  Clopidogrel Hyper-Response and Bleeding Risk in Neurointerventional Procedures , 2013, American Journal of Neuroradiology.

[18]  C. Cannon,et al.  Inhibitory effects of ticagrelor compared with clopidogrel on platelet function in patients with acute coronary syndromes: the PLATO (PLATelet inhibition and patient Outcomes) PLATELET substudy. , 2010, Journal of the American College of Cardiology.

[19]  B. Kwon,et al.  Preinterventional Clopidogrel Response Variability for Coil Embolization of Intracranial Aneurysms: Clinical Implications , 2010, American Journal of Neuroradiology.

[20]  Michael D Hill,et al.  Stenting versus endarterectomy for treatment of carotid-artery stenosis. , 2010, The New England journal of medicine.

[21]  K. Tan,et al.  Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial , 2010, The Lancet Neurology.

[22]  R. Teng,et al.  Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects , 2010, European Journal of Clinical Pharmacology.

[23]  Mark J. Antonino,et al.  Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease: The ONSET/OFFSET Study , 2009, Circulation.

[24]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[25]  J. Saw,et al.  Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. , 2009, Journal of the American College of Cardiology.

[26]  G. Patti,et al.  Clinical ResearchInterventional CardiologyPoint-of-Care Measurement of Clopidogrel Responsiveness Predicts Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention: Results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reacti , 2008 .

[27]  Samin K. Sharma,et al.  Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. , 2008, American heart journal.

[28]  Hashem Shaltoni,et al.  Dual Antiplatelet Therapy Monitoring for Neurointerventional Procedures Using a Point-of-Care Platelet Function Test: A Single-Center Experience , 2008, American Journal of Neuroradiology.

[29]  J. Tardif,et al.  Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. , 2008, Journal of the American College of Cardiology.

[30]  C. Cannon,et al.  Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. , 2007, Journal of the American College of Cardiology.

[31]  C. Cannon,et al.  Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. , 2007, Journal of the American College of Cardiology.

[32]  B. Griffin,et al.  Clopidogrel loading doses and outcomes of patients undergoing percutaneous coronary intervention for acute coronary syndromes. , 2007, The Journal of invasive cardiology.

[33]  A. Qureshi.  Carotid angioplasty and stent placement after EVA-3S trial. , 2007, Stroke.

[34]  E. Peterson,et al.  ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting , 2007 .

[35]  Xavier Ducrocq,et al.  Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. , 2006, The New England journal of medicine.

[36]  W. Hacke,et al.  30 day results from the SPACE trial of stent-protected angioplasty versus carotid endarterectomy in symptomatic patients: a randomised non-inferiority trial , 2006, The Lancet.

[37]  P. Morange,et al.  Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. , 2006, Journal of the American College of Cardiology.

[38]  Y. Gologorsky,et al.  Initial experience with the use of intravenous eptifibatide bolus during endovascular treatment of intracranial aneurysms. , 2006, AJNR. American journal of neuroradiology.

[39]  G. Montalescot,et al.  A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. , 2006, Journal of the American College of Cardiology.

[40]  K. Kent,et al.  Clopidogrel loading dose (300 versus 600 mg) strategies for patients with stable angina pectoris subjected to percutaneous coronary intervention. , 2006, The American journal of cardiology.

[41]  S. Steinhubl,et al.  Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. , 2006, Journal of the American College of Cardiology.

[42]  A. Kastrati,et al.  Absorption, Metabolization, and Antiplatelet Effects of 300-, 600-, and 900-mg Loading Doses of Clopidogrel: Results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial , 2005, Circulation.

[43]  P. Gaines,et al.  The benefits of combined anti-platelet treatment in carotid artery stenting. , 2005, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[44]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[45]  T. Bajwa,et al.  Protected carotid-artery stenting versus endarterectomy in high-risk patients. , 2004, The New England journal of medicine.

[46]  A. Qureshi,et al.  Safety of High-dose Intravenous Eptifibatide as an Adjunct to Internal Carotid Artery Angioplasty and Stent Placement: A Prospective Registry , 2004, Neurosurgery.

[47]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[48]  P. Järemo,et al.  Individual variations of platelet inhibition after loading doses of clopidogrel , 2002, Journal of internal medicine.

[49]  J. Suarez,et al.  Intracerebral Hemorrhages Associated With Neurointerventional Procedures Using a Combination of Antithrombotic Agents Including Abciximab , 2002, Stroke.

[50]  A. Ringer,et al.  Carotid Angioplasty and Stent Placement: A Prospective Analysis of Perioperative Complications and Impact of Intravenously Administered Abciximab , 2002, Neurosurgery.

[51]  A. Narata,et al.  Dual Antiplatelet Therapy Combining Aspirin and Ticagrelor for Intracranial Stenting Procedures: A Retrospective Single Center Study of 154 Consecutive Patients With Unruptured Aneurysms , 2019, Neurosurgery.

[52]  N. Toma.  Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of Ticagrelor versus Clopidogrel in patients with stable coronary artery disease. The ONSET/OFFSET study. , 2010, Maedica.

[53]  A. Germing.  Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis , 2007 .

[54]  R. Harrington.  “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study” , 2005 .